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Summary Introduction: Combined-modality treatment is considered standard of
care in the treatment of stage III non-small-cell lung cancer (NSCLC). This study was
designed to assess the efficacy and tolerability of induction paclitaxel/carboplatin
followed by concurrent thoracic radiotherapy and weekly paclitaxel.
Materials and methods: Patients with unresectable stage III NSCLC were treated
prospectively with two cycles of paclitaxel (175mg/m2) and carboplatin (area under
the curve of 6) followed by radiotherapy (60–66Gy) concurrent with 6 weekly doses
of paclitaxel (60mg/m2). Response was determined 8 weeks after the completion of
treatment and treatment-related toxicities were assessed at each visit during
treatment and follow-up.
Results: Sixty-three patients were treated, 5 had complete response and 33 had
partial response, giving a response rate of 60%. Thirty-seven percent of patients
developed grade 3 or 4 neutropenia; 48% had significant esophagitis requiring the use
of narcotic analgesics. Two patients developed esophageal stricture subsequently.
The median survival was 51 months and 12 months for stage IIIA and IIIB patients,
respectively. Progression-free survival was 16months and 11months respectively.
Conclusions: The response rate was encouraging. Esophagitis was a significant
morbidity and should prompt modification of treatment regimen, either in the
chemotherapy schedule or by adjusting the radiotherapy treatment planning.
& 2004 Elsevier Ltd. All rights reserved.
Introduction and purpose
In the last decade, combined-modality treatment
has taken the management of locally advanced
non-small cell lung cancer (NSCLC) to a new level
with improved disease control and median survi-
val.1–5 Different treatment schedules have been
explored, ranging from sequential use of che-
motherapy and radiotherapy,3,6 to concurrent
chemo-radiotherapy,4,5,7 to a combination of both
(with chemotherapy given either upfront8 or
following concurrent treatment9,10). Some regimen
also included surgical resection as an integral part
of the treatment.1,2,6,11
Amongst the various chemotherapy agents
used, paclitaxel/carboplatin remained one of the
more popular combinations.9,10 Preclinical studies
have shown paclitaxel to potentiate the effects of
ARTICLE IN PRESS
KEYWORDS
Combined-modality;
Esophagitis;
Locally advanced;
Neurotoxicity;
Neutropenia
*Corresponding author. Tel.: þ 65-6436-8174; fax: þ 65-6227-
2759.
E-mail address: dmolss@nccs.com.sg (S.S. Leong).
0954-6111/$ - see front matter & 2004 Elsevier Ltd. All rights reserved.
doi:10.1016/j.rmed.2004.03.020
Respiratory Medicine (2004) 98, 1080–1086
radiotherapy12,13 and its radiosensitizing properties
formed the basis for its concurrent use during
thoracic radiotherapy. The combination of pacli-
taxel and carboplatin have consistently shown
significant efficacy in the treatment of NSCLC.
Langer and colleagues, in their trial of treating
stage IIIB and IV patients with this combination,
demonstrated a response rate of 62%.14 In another
similar study by Johnson et al., the combination
yielded a response rate of 27% and a 1-year survival
rate of 32%.15 In the treatment of locally advanced
NSCLC, this combination has given response rates of
between 52% to 86% when used concurrently with
thoracic radiotherapy. 9,10
Combined-modality treatment, although result-
ing in better disease control, has been limited by
heightened toxicities. This appeared to be true
regardless of the type of treatment schedule or the
chemotherapeutic agents used and the challenge is
thus to be able to reduce treatment toxicities while
not compromising outcome. In a bid to improve the
therapeutic index of future treatment, it is
important to establish our own institution baseline
in terms of treatment toxicities and response rates
using one such regimen. We prospectively treated
consecutive stage III NSCLC patients with induction
paclitaxel/carboplatin followed by concurrent pa-
clitaxel with radiotherapy.
Patients and methods
Eligibility criteria
Stage III NSCLC patients (excluding those with
malignant pleural effusion) who had not received
previous treatment were eligible for the study.
They had to be 18 years of age or older, had
performance status of p2 on the Eastern Co-
operative Oncology Group (ECOG) scale, with no
severe co-morbid conditions or other malignancies
in the preceding 5 years. Patients in whom disease
were considered suitable for eventual resection
were excluded from this study. Adequate hemato-
logic, renal and hepatic functions, defined as
neutrophil count of 1.0 109/l or greater, platelet
count of 100 109/l or greater, serum creatinine of
less than 140 mmol/l, bilirubin level less than 1.5
times upper normal limit, serum alkaline phospha-
tase and liver enzyme levels less than 3 times upper
normal limit, were required. There had to be bi-
dimensionally measurable disease on computed
tomography (CT) scan of at least 1 cm in one
diametre. Approval was obtained from the Ethics
Committee of Singapore General Hospital.
Chemotherapy
Two cycles of induction chemotherapy were given
at 3-weekly intervals. If there were no disease
progression, treatment would continue for another
6 weeks with radiotherapy and weekly chemother-
apy given concurrently.
Induction chemotherapy consisted of paclitaxel
175mg/m2, given as a 3-h intravenous infusion,
followed by carboplatin dosed to a target area
under the concentration–time curve of 6 (AUC¼ 6)
as determined by the Calvert formula.16 The
paclitaxel/carboplatin combination was given on
days 1 and 22. All patients received oral dexa-
methasone 20mg at 12 and 6 h before the che-
motherapy, and intravenous cimetidine 300mg,
diphenhydramine 50mg and granisetron 3mg at
30min before paclitaxel infusion. During concur-
rent chemo-radiotherapy, paclitaxel was given
once a week (on days 43, 50, 57, 64, 71, 78) at a
dose of 60mg/m2 as a 1-h infusion. Pre-medication
was similar to that for the induction treatment.
Treatment modification was required if the abso-
lute neutrophil count was less than 1.0 109/l or if
the platelet count was less than 100 109/l; if the
patient developed any grade 3 or 4 non-hematologi-
cal toxicities; or if there were infections or other
serious adverse events. If the above occurred during
the induction phase, administration of the second
cycle of chemotherapy would be delayed till recovery
of blood counts and/or other toxicities to grade 2 or
less. During the concurrent phase, chemotherapy was
omitted for the week and resumed when the
condition has improved or resolved.
Radiotherapy
Patients received radiation in two phases. In phase
one, antero-posterior portals were conventionally
simulated to enclose the primary tumour and the
ipsilateral hilar and mediastinal nodal stations (for
N2 disease) or more uncommonly the entire
mediastinum and ipsilateral hilum (for N3 disease)
from the lower pre-trachael to the subcarinal
groups. Elective irradiation of the ipsilateral
supraclavicular fossa for upper lobe tumours was
optional. A margin of 2 cm around radiographically
evident tumour was maintained. A dose of 40Gy in
2Gy daily fractions over 4 weeks was delivered to
the 100% isodose using a 6 or 10MV photon beam.
In phase 2, a therapy CT scan was performed to
delineate gross tumour and a reduced volume with
a 2 cm margin around the gross tumour was treated
to an additional 20Gy in 10 daily fractions using a 6
or 10MV photon beam. The spinal cord was allowed
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a maximum cumulative dose of 46Gy over the
entire course of treatment.
Pretreatment evaluation
All patients had a detailed medical history and
physical examination before enrollment. Baseline
investigations included a complete blood cell
count, serum electrolytes and creatinine, liver
function tests. Computed tomography scan of the
thorax and upper abdomen were done within 30
days prior to enrollment. Bone scan and CT scan of
the head were done if there were clinical suspicion
of metastasis to those sites.
Evaluation of response
Response to treatment was determined on CT scan
using World Health Organization (WHO) criteria:
complete response (CR) defined as complete
disappearance of all measurable and assessable
disease; partial response (PR) defined as a greater
than or equal to 50% reduction in the sum of the
products of the longest diameter and its perpendi-
cular for each lesion; progressive disease (PD)
occurred if this sum increased by 25% or greater;
and stable disease (SD) defined as response less
than a PR but not reaching PD. Computed tomo-
graphy scan was performed on week 6 to assess for
response to induction treatment. Patients who had
CR, PR or SD could proceed to receive chemo-
radiotherapy. Radiological evaluation was repeated
8 weeks after the completion of chemo-radio-
therapy and this was considered the overall
treatment response.
Evaluation of toxicities
Patients were assessed at 3-weekly intervals during
induction treatment and weekly during chemo-
radiotherapy. Toxicities were assessed via direct
questioning and physical examination, using the
National Cancer Institute (NCI) Common Toxicity
Criteria. Evaluation of esophagitis was based on the
Radiation Therapy Oncology Group (RTOG) criteria.
After treatment, patients were followed up at 3-
monthly intervals (or earlier if clinically indicated)
for the first 2 years and 6-monthly thereafter, till
disease progression or death. Disease progression
and late toxicities were evaluated at these visits.
Statistical analysis
The overall response rate was expressed as the
proportion of patients demonstrating a CR or a PR
based on the total number of patients enrolled on
the study. The overall survival (OS) and progression-
free survival (PFS) curves were computed from the
date of study entry, using the Kaplan–Meier
method17 and comparisons between stage IIIA and
stage IIIB patients carried out using the logrank
statistics.18 All analyses of response rate and
toxicity were performed according to intent-to-
treat.
Results
Patient characteristics
Sixty-three patients were accrued between August
1997 and February 2000, of which 13 (21%) were
female and the rest (79%) were male. The age of
patients ranged from 33 to 77 with a median of 65.
Seventeen patients (27%) had stage IIIA disease and
46 (73%) had stage IIIB disease. Twenty-three
patients (37%) had squamous cell carcinoma; 15
(24%) had large cell carcinoma; 16 (25%) had
adenocarcinoma and in 9 cases (14%) the cell type
was not specified.
Treatment received
At evaluation after the induction treatment, 3
patients had CR, 29 had PR and 14 had SD. These 46
patients went on to receive chemo-radiotherapy. In
addition, 5 patients who did not have interim CT
scan but who had no clinical evidence of progres-
sion also went on to the concurrent treatment
phase. Of the remaining 12 patients, 3 had PD; 2
refused further treatment; 1 was taken off study
because of unstable angina; and there were 6 early
deaths.
Of the 51 patients who received concurrent
chemo-radiotherapy, 40 (63% of all patients ac-
crued) received all 6 doses of weekly paclitaxel.
Nine patients had interruption of the weekly
chemotherapy because of toxicities. One patient
died from pulmonary embolism during week 4 and
one patient refused the last 2 doses of chemother-
apy. Forty-six patients (73%) received the planned
radiotherapy of at least 60Gy. Four patients
received only 50–56Gy and the patient who died
from pulmonary embolism received only 44Gy.
[Table 1]
Thirty patients also received amifostine 740mg/
m2 before each dose of chemotherapy. There was
no statistically significant impact on toxicities and
survival19 and hence no separate analysis was
discussed in this report.
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Response and survival
Final response was evaluated 8 weeks after
completion of treatment. Five patients had CR,
33 patients had PR, 1 patients had SD and 11
patients progressed. The response rate from the
treatment (CR þ PR) was 60%. Thirteen patients
were not evaluable: 8 died during the course of
treatment (Table 2); 3 decided to withdraw before
completion; 1 patient was taken off study for
unstable angina and 1 patient defaulted CT scan
evaluation.
At the time of analysis, 49 patients have died.
The median duration of follow-up among the
surviving patients was 46 months. Forty-one
patients had documented progression. Local recur-
rence was the first site of failure (without distant
metastasis) in 24 patients, 10 patients had distant
metastases only and 7 patients progressed both
locally and at distant sites (Table 3).
The 5-year survival of all patients was 15%. The
median survival was 51 months for patients with
stage IIIA disease and 12 months for patients with
stage IIIB disease. (P¼ 0.0128) (Fig. 1). Progression-
free survival was 16 months for stage IIIA patients
and 11 months for stage IIIB patients (P¼ 0.2772)
(Fig. 2).
Toxicity
Acute and late toxicities were evaluated using NCI
common toxicity criteria and RTOG criteria. The
main toxicities were hematological toxicity and
esophagitis. Twenty-three patients (37%) had grade
3 or 4 neutropenia. All were documented during the
induction chemotherapy phase. Nadir counts oc-
curred usually during the third week of chemother-
apy cycles and did not result in compromise of dose
intensities. However, one patient developed neu-
tropenic sepsis and he died as a result of the
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Table 1 Treatment received.
Enrollment 
n = 63 
Induction chemotherapy
CR, PR, SD (n = 46) OffNo evidence of PD (n = 5) 
   n = 12 n = 51 
Chemoradiotherapy
PD (n = 3) 
death (n = 6) 
angina (n = 1) 
Completed chemotherapy as planned (n = 40)
Completed radiotherapy as planned    (n = 46)
study
Table 2 Mortality during treatment.
Cause of death Number of
patients
Treatment-related
Acute pulmonary edema 1
Neutropenic sepsis 1
Unknown (died within 14 days) 2
Progression of disease 2
Hemoptysis 1
Pulmonary embolism 1
Table 3 Presentation at first progression/recur-
rence.
Site of first recurrence Number of patients
(% of all patients)
Local (all) 31 (49%)
Liver 4 (6%)
Bone 6 (10%)
Brain 8 (13%)
Lungs (disseminated/
contralateral)
8 (13%)
Both local and distant 7 (11%)
Fig. 1
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complication. Two patients (3%) had grade 3
anemia and none had4grade 1 thrombocytopenia.
Thirty patients (48%) had grade 2 (requiring the
use of narcotic analgesics) or grade 3 (requiring
nasogastric tube feeding, intravenous fluids or
hyperalimentation) esophagitis. Esophagitis typi-
cally presented during the third or fourth week of
chemo-radiotherapy and could take up to 6 weeks
after the treatment to resolve.
Other significant toxicities included grade 3
fatigue in 12 patients and grade 3 neurotoxicity in
4 patients (Table 4). Late toxicities were monitored
during subsequent follow-up. Two patients who had
grade 2 esophagitis eventually developed esopha-
geal stricture. Both were females. One patient
required endoscopic dilatation while the other
patient improved spontaneously over 6 months.
There were 4 treatment-related deaths. One
patient died from acute pulmonary edema after
first cycle of chemotherapy; one patient developed
perforated duodenal ulcer and subsequently suc-
cumbed from neutropenic sepsis after surgical
repair; two patients died within 2 weeks of the
first cycle of induction chemotherapy.
Discussion
For a long time, locally advanced NSCLC was
treated with radiotherapy alone. This gave a
response rate of 45–60% but recurrence invariably
occurred early, and the median survival was less
than one year.20 The breakthrough came when
investigators demonstrated improved survival by
combining the use of different treatment modal-
ities.1–3 Later studies in patients not amenable to
surgery also showed superiority of chemotherapy
and radiotherapy given concurrently, over sequen-
tial treatment.21 The benefit was felt to be due to
the dual action of systemic as well as radio-
sensitization effect of chemotherapy when given
concurrent with radiotherapy. What was still not
clear was whether upfront chemotherapy, before
concurrent chemo-radiotherapy, could improve on
systemic control and survival.
Many studies in the last decade have explored
the use of different chemotherapy agents3–9 and
different radiotherapy schedules.6,8 Paclitaxel with
carboplatin had been one of the more frequently
used combinations with response rate in excess of
50%.9,10,22 Our current study aimed to assess the
efficacy and tolerability of a regimen, which
combined the concepts of induction chemotherapy
(for early systemic control) and concurrent chemo-
radiotherapy. Paclitaxel and carboplatin was the
chemotherapy used and radiotherapy was given as
standard, once daily fractions of 2Gy a day for
60Gy.
The results were encouraging, with an overall
response rate of 60%. This was consistent with
efficacy expected of a combined-modality treat-
ment schedule. The 5-year survival rate of all
patients was 15% and the median survival was 51
months and 12 months for stage IIIA and stage IIIB
patients, respectively.
The treatment regimen was well tolerated
except for esophagitis. This toxicity was a by-
product of enhancement of radiotherapy and a
direct result of concurrent chemo-radiotherapy
treatment. In order to improve the therapeutic
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Table 4 Toxicity of treatment.
Toxicity grading Number of patients
1 2 3 4
Hematological
Anemia 29 19 2 0
Neutropenia 5 17 16 7
Thrombocytopenia 10 0 0 0
Non-hematological
Nausea 16 11 1 0
Vomiting 16 6 2 0
Diarrhoea 11 4 0 0
Constipation 26 9 4 0
Fatigue 17 22 12 0
Alopecia 6 42 F F
Sensory 37 7 3 0
Motor 10 5 2 0
Esophagitis 8 25 5 0
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index, it will be imperative to find means of
reducing this toxicity. One way of achieving this
is to change the chemotherapy agents or schedule
since some treatment regimen have been shown to
be associated with a lower incidence of esophagi-
tis.8,23 Another method is to use a radioprotector
that selectively protects normal tissue.24,25 It
will also be interesting to explore the role of
using positron emission tomography scan and
three-dimensional conformal radiotherapy to bet-
ter define and limit the radiotherapy treatment
field.
Whilst it is important to explore ways of reducing
toxicities, the more important task is to improve
treatment efficacy and improve survival. The
generally poor outcome is usually due to systemic
failure and majority of patients who had received
combined-modality treatment would still relapse or
progress despite initial response to treatment. In
our study, 65% (n¼ 41) of patients have relapsed or
progressed at the time of analysis. Seventy-six
percent of relapsed patients had local disease and
41% presented with distant metastasis at the time
of relapse. Looking at the pattern of relapse with
different treatment schedules reported over the
years, the proportion of patients with local disease
as first site of relapse was as high as 90% when
chemotherapy and radiotherapy was given sequen-
tially.3 When concurrent schedules were used, this
was markedly reduced,10 as was also evident in the
current study. This was evidence of the impact on
local control when radiotherapy was enhanced by
the addition of chemotherapy. On the other hand,
contrary to an intuitive assumption that giving full
dose chemotherapy in addition to concurrent
treatment will reduce the rate of distant relapse,
this was not apparent in our study. Distant relapse
of about 60% have also been reported when no
induction treatment was given.21 In another study
by Dr. Choy and colleagues, giving 2 cycles of
paclitaxel and carboplatin after concurrent chemo-
radiotherapy also did not seem to significantly alter
the distant failure rate.10 It would appear that a
plateau may have been reached in terms of
treatment results using currently accepted stan-
dard of combined chemotherapy and radiotherapy
with or without surgery, for this very specific group
of patients. While research continues with the use
of other chemotherapy regimen26,27 with seemingly
encouraging results, it is timely that attention is
now turned towards incorporation of targeted
therapies. This strategy has already been explored
in patients with advanced disease28,29 and it
remains to be seen if it will make an impact on
the treatment of patients with locally advanced
non-small cell lung cancer.30
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